APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma
about
The varied distribution and impact of RAS codon and other key DNA alterations across the translocation cyclin D subgroups in multiple myelomaStructural determinants of APOBEC3B non-catalytic domain for molecular assembly and catalytic regulationWhole-exome sequencing of primary plasma cell leukemia discloses heterogeneous mutational patterns.Genome-wide association study identifies multiple susceptibility loci for multiple myeloma.An APOBEC3A hypermutation signature is distinguishable from the signature of background mutagenesis by APOBEC3B in human cancersCrystal Structure of the DNA Deaminase APOBEC3B Catalytic Domain.Inhibiting the oncogenic translation program is an effective therapeutic strategy in multiple myeloma.Clinical value of molecular subtyping multiple myeloma using gene expression profilingA new strategy for exploring the hierarchical structure of cancers by adaptively partitioning functional modules from gene expression network.Nuclear Magnetic Resonance Structure of the APOBEC3B Catalytic Domain: Structural Basis for Substrate Binding and DNA Deaminase Activity.The DNA cytosine deaminase APOBEC3H haplotype I likely contributes to breast and lung cancer mutagenesis.The Spectrum and Clinical Impact of Epigenetic Modifier Mutations in Myeloma.Molecular classification of tissue from a transformed non-Hogkin's lymphoma case with unexpected long-time remission.Reactivation of dormant anti-tumor immunity - a clinical perspective of therapeutic immune checkpoint modulation.The LIN28B/let-7 axis is a novel therapeutic pathway in multiple myelomaBi-allelic inactivation is more prevalent at relapse in multiple myeloma, identifying RB1 as an independent prognostic marker.Proteome alterations associated with transformation of multiple myeloma to secondary plasma cell leukemia.Identification of key genes and construction of microRNA-mRNA regulatory networks in multiple myeloma by integrated multiple GEO datasets using bioinformatics analysis.Neutral tumor evolution in myeloma is associated with poor prognosis.Utilizing next-generation sequencing in the management of multiple myeloma.Overexpression of B-cell lymphoma 6 alters gene expression profile in a myeloma cell line and is associated with decreased DNA damage response.Whole-genome sequencing of chronic lymphocytic leukaemia reveals distinct differences in the mutational landscape between IgHVmut and IgHVunmut subgroups.Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients.The spectrum of somatic mutations in monoclonal gammopathy of undetermined significance indicates a less complex genomic landscape than that in multiple myeloma.Genomic Aberrations in Multiple Myeloma.MGUS to myeloma: a mysterious gammopathy of underexplored significance.RPL5 on 1p22.1 is recurrently deleted in multiple myeloma and its expression is linked to bortezomib response.Multiple myeloma risk variant at 7p15.3 creates an IRF4-binding site and interferes with CDCA7L expressionMutational Signatures in Breast Cancer: The Problem at the DNA LevelPreliminary Application of Precision Genomic Medicine Detecting Gene Variation in Patients with Multifocal Osteosarcoma.Genetic Predisposition to Multiple Myeloma at 5q15 Is Mediated by an ELL2 Enhancer Polymorphism.APOBEC3B is an enzymatic source of molecular alterations in esophageal squamous cell carcinoma.Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma.Correlation of Apobec Mrna Expression with overall Survival and pd-l1 Expression in Urothelial Carcinoma.Concomitant gain of 1q21 and MYC translocation define a poor prognostic subgroup of hyperdiploid multiple myeloma.Biological and prognostic impact of APOBEC-induced mutations in the spectrum of plasma cell dyscrasias and multiple myeloma cell lines.Conformational Switch Regulates the DNA Cytosine Deaminase Activity of Human APOBEC3B.High somatic mutation and neoantigen burden are correlated with decreased progression-free survival in multiple myeloma.Evolutionary biology of high-risk multiple myeloma.Tumour heterogeneity and resistance to cancer therapies.
P2860
Q33709470-4B7EDC36-AAF3-4E66-8381-7DB78A110707Q33878087-08B535D3-70E6-49B7-B136-13E19C488ACCQ34479418-019B43C8-0690-461B-9C38-2C8C4751B0E8Q34677689-07CBC16E-1D90-4176-8F63-C24C436D21E6Q36123927-9A6810BD-B073-471B-B4A4-19CA0AE5A0A6Q36301232-6ABCAA8E-2685-4EED-B6B4-CA0923363415Q36368265-47EC4925-FA6C-400B-94EA-10BE4D798CC2Q36540781-505CD062-CB53-4130-92D4-E047937D8462Q37044458-6A7039CA-268F-42C9-923A-AD5E56ED71CEQ37091342-75574183-2D3C-4A6B-8AD4-7745CC605201Q37281847-700CCBF7-8E7D-4D4D-BB9E-6E402404488DQ37443338-FEE52CA7-E5C3-4B2C-A330-95827BAA47EFQ37579101-A7BE4638-066E-416A-9E68-5E8B0875BD42Q37593573-529D0A76-D61C-4BBB-814C-3755F0AD330FQ37739051-92783A2D-E0DC-407C-B5FA-1B790000D9ACQ37744796-63502D4B-37D4-4C15-9F54-C221B890E177Q37746021-BA75CEF2-D80E-487B-9D95-F8001E05B5F6Q38435781-0248E90A-23FA-40CF-A0D2-C6C231EF726CQ38615431-E1C70844-91FA-4113-AE6C-EA2D89E38A45Q38681814-9A2EF157-53B6-42E3-BD1B-61F92E82E705Q38702294-FA4E875B-7920-4342-A179-C415F55797A6Q38742049-6FB7D196-61EE-4D2D-81DF-D02DB3F03A35Q38742055-3E1BAD27-07C8-4AC6-900C-2E32B892BBABQ38760679-E8353779-92C5-43F0-B077-6D1569E87527Q38970573-0C92953E-0E3F-42EC-85B5-1A864B3A5F15Q38979865-9D93297B-0066-45C8-9377-FC58F36C1E4DQ39137868-F6EE756C-0E51-4C00-B2C3-00236B3A21E0Q39156834-ABF757C3-4EBB-4ED7-B569-87567EBD5FD3Q39345007-A6EBB79A-1D11-4CAC-9BCC-2B518FD948A5Q39626573-F72FE171-16C7-41B0-AE89-196CEA088F85Q40043371-1A4FA846-37F5-42BE-8C62-7396877570D1Q40908304-1777552A-0E3A-4420-9F8F-D673B797408BQ41663752-CF2FCFA1-298F-4AF8-ACBB-9519FF1C7325Q42575965-BA9ECF3D-7BCD-47F8-8CDF-C0ED687AB015Q42923836-3469CCCE-6FFB-477D-97A4-87AB7D5A5BEFQ46265856-229F4A37-E483-4928-9D1E-2065607AC348Q46844461-1624132C-F574-4F9C-A5C2-5BA5A72F846BQ47100879-93056F53-FADB-4946-BAAE-5C2152BD74B0Q47913337-4C62085A-427D-499D-A09C-4CA08BF2AD27Q50112440-C5252375-43FE-4373-9F2D-D6BBE4916047
P2860
APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
APOBEC family mutational signa ...... slocations in multiple myeloma
@ast
APOBEC family mutational signa ...... slocations in multiple myeloma
@en
APOBEC family mutational signa ...... slocations in multiple myeloma
@en-gb
type
label
APOBEC family mutational signa ...... slocations in multiple myeloma
@ast
APOBEC family mutational signa ...... slocations in multiple myeloma
@en
APOBEC family mutational signa ...... slocations in multiple myeloma
@en-gb
prefLabel
APOBEC family mutational signa ...... slocations in multiple myeloma
@ast
APOBEC family mutational signa ...... slocations in multiple myeloma
@en
APOBEC family mutational signa ...... slocations in multiple myeloma
@en-gb
P2093
P2860
P50
P356
P1154
2-s2.0-84928558756
P1476
APOBEC family mutational signa ...... slocations in multiple myeloma
@en
P2093
Alex Murison
David A Cairns
Dil B Begum
Faith E Davies
Graham H Jackson
John R Jones
Lorenzo Melchor
Mark T Drayson
Martin F Kaiser
Nasrin M Dahir
P2860
P2888
P356
10.1038/NCOMMS7997
P407
P50
P5530
P577
2015-04-23T00:00:00Z
P5875
P6179
1020039215